Drug trial falters

September 1991
New Scientist;9/21/91, Vol. 131 Issue 1787, p20
The article focuses on the announcement regarding the recruitment of participants by the world's only large-scale trial of the AIDS drug ddI. The AIDS drug ddI has stopped recruiting participants. Alpha, a trial run by Great Britain's Medical Research Council and France's INSERM, offers people either option A, which gives them equal chances of a placebo or the drug; or option B, which gives either a high or low dose of the drug. But only some 20 people chose option A.


Related Articles

  • Commentary. Chaplin, Robert // Evidence Based Mental Health;Feb2007, Vol. 10 Issue 1, p15 

    The article offers the author's comment on the result of a medical research related to the efficacies of the atypical antipsychotics, risperidone and quetiapine, and placebo intended for patients with schizophrenia in Great Britain. The author knowledge such study on the comparative efficacy of...

  • Rivaroxaban: an oral, factor Xa inhibitor. Elliott, William T. // Neurology Alert;Feb2011 Primary Care, p1 

    The article offers an overview of a research study which suggests the efficacy of rivaroxaban for the treatment of acute deep vein thrombosis (DVT), which appeared in the 2010 issue of the "New England Journal of Medicine." Based on results, rivaroxaban was non-inferior to enoxaparin-vitamin K...

  • Review: over-the-counter medications are effective for gastro-oesophageal reflux disease. Strickland, D. Shane // Evidence Based Nursing;Jul2007, Vol. 10 Issue 3, p76 

    The article discusses research which concluded that over-the-counter medications are effective for gastro-oesophageal reflux disease. Antacids offered higher subjective improvement and less use of rescue antacids than placebo. The alginate-antacid combination provided greater subjective...

  • New study finds that PROMETAT, a controversial methamphetamine treatment program, is ineffective.  // Biomedical Market Newsletter;11/21/2011, Vol. 21, p666 

    The article presents a study which found that PROMETAT, a popular but controversial treatment for methamphetamine addiction is not effective than placebo in reducing methamphetamine use in the U.S. It mentions that methamphetamine is the second most abused illicit drug in the world. It states...

  • Examining the Clinical Utility of Lacosamide. Chung, Steve; Ben-Menachem, Elinor; Sperling, Michael R.; Rosenfeld, William; Fountain, Nathan B.; Benbadis, Selim; Hebert, David; Isojärvi, Jouko; Doty, Pamela // CNS Drugs;2010, Vol. 24 Issue 12, p1041 

    Background: Lacosamide is an antiepileptic drug (AED) approved for the adjunctive treatment of partial-onset seizures in adults. Completed phase II/III clinical trials of lacosamide provide a valuable opportunity to evaluate clinically relevant aspects of the resulting large patient pool....

  • Ecallantide: In Acute Hereditary Angioedema. Garnock-Jones, Karly P. // Drugs;2010, Vol. 70 Issue 11, p1423 

    Ecallantide, a recombinant protein that is a selective, highly potent and reversible inhibitor of human plasma kallikrein, is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in patients aged ≥16 years. In the randomized, double-blind, placebo-controlled,...

  • The rate vs rhythm debate. Elliott, William T. // Travel Medicine Advisor;Apr2009 Pharmacology Watch, p1 

    The article discusses research on the effects of the drug dronedarone, a derivative of amiodarone, in patients with atrial fibrillation (AF). It references a study published in a 2009 issue of the "New England Journal of Medicine." Clinical data showed that drug lowered hospitalization and death...

  • Canada has a DREAM.  // Wellness Options;2006, Issue 28, p10 

    The article looks at the diabetes prevention trial known as Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication. The study found that while more recipients of both ramipril and rosiglitazone became normoglycemic compared with the placebo recipients, only rosiglitazone, a...

  • Composite End points: Proceed with Caution. Kleist, Peter // Applied Clinical Trials;May2006, Vol. 15 Issue 5, p50 

    The article discusses the use of valid primary endpoint for a randomized controlled trial (RCT) designed to demonstrate efficacy of a new pharmaceutical drug in clinical trials. A composite endpoint consists of multiple single endpoints that are combined in order to confront an investigational...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics